Receptor tyrosine kinase therapeutic monoclonal antibodies

The therapeutic challenges of receptor tyrosine kinases
SYnAbs generates custom therapeutic monoclonal antibodies to receptor tyrosine kinases (RTKs) thanks to proprietary technologies and unique expertise
Anti-CD25 therapeutic monoclonal antibody strategies
SYnabs unique anti-CD25 anti-IL2R therapeutic antibody has shown great promise in clinical trials. SYnAbs antagonist anti-IL2Ra/Tac depletes Tregs for GvHD and cancer treatments.

IL1RAP, a new biomarker of interest for cancer targeting
735. 735 autopsy reports. Report after report, the conviction of Stephen was growing. What he was observing could not have happened by chance. This time, he was sure. A pattern was emerging. His hypothesis was finally confirmed. His father James had been a successful surgeon, founder of the modern scientific pathology, but his discovery could make him even more famous. The impact of what he had in front of him was far greater. He picked up his stylograph, look at the date on the